# Scilex Holding Co: overview SCLX · Nasdaq · CIK 1820190 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/sclx.md) · [Financials](/companies/sclx/financials.md) · [Filings](/companies/sclx/filings.md) · [Insiders](/companies/sclx/insiders.md) Latest reported revenue: [$7.6m](/filings/0001193125-26-352464.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-352464). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [14.4](/filings/0001193125-25-283153.md) | [14.9 d](/filings/0001193125-26-151455.md) | [5.0](/filings/0001193125-26-232857.md) | [9.9](/filings/0001193125-26-352464.md) | [10.6](/filings/0001193125-25-283153.md) | [4.8 d](/filings/0001193125-26-151455.md) | [8.6](/filings/0001193125-26-232857.md) | [7.6](/filings/0001193125-26-352464.md) | | Gross margin | % | not reported | not reported | [353.7%](/filings/0001193125-26-232857.md) | [399.2%](/filings/0001193125-26-352464.md) | not reported | not reported | [298.4%](/filings/0001193125-26-232857.md) | [206.8%](/filings/0001193125-26-352464.md) | | Operating margin | % | [(138.0%)](/filings/0001193125-25-283153.md) | [(190.5%) d](/filings/0001193125-26-151455.md) | [(557.5%)](/filings/0001193125-26-232857.md) | [(207.2%)](/filings/0001193125-26-352464.md) | [(1766.2%)](/filings/0001193125-25-283153.md) | [(2317.8%) d](/filings/0001193125-26-151455.md) | [(373.5%)](/filings/0001193125-26-232857.md) | [(385.0%)](/filings/0001193125-26-352464.md) | | Net margin | % | [(30.4%)](/filings/0001193125-25-283153.md) | [(43.4%) d](/filings/0001193125-26-151455.md) | [(521.2%)](/filings/0001193125-26-352464.md) | [(445.1%)](/filings/0001193125-26-352464.md) | [(2441.5%)](/filings/0001193125-25-283153.md) | [(961.9%) d](/filings/0001193125-26-151455.md) | [(530.0%)](/filings/0001193125-26-352464.md) | [(1504.7%)](/filings/0001193125-26-352464.md) | | Diluted EPS | $ per share | [(0.58)](/filings/0001193125-25-283153.md) | not reported | [(2.26)](/filings/0001193125-26-232857.md) | [(7.42)](/filings/0001193125-26-352464.md) | [(22.17)](/filings/0001193125-25-283153.md) | not reported | [(6.28)](/filings/0001193125-26-232857.md) | [(16.65)](/filings/0001193125-26-352464.md) | | Free cash flow | $m | [5.1 d](/filings/0001193125-25-283153.md) | [2.5 d](/filings/0001193125-26-151455.md) | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Gross profit: us-gaap:GrossProfit. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [31.3](/filings/0000950170-24-029473.md) | [38.0](/filings/0000950170-24-029473.md) | [46.7](/filings/0000950170-25-047800.md) | [56.6](/filings/0001193125-26-151455.md) | [30.3](/filings/0001193125-26-151455.md) | | Gross margin | % | not reported | not reported | not reported | [295.8%](/filings/0001193125-26-151455.md) | [415.8%](/filings/0001193125-26-151455.md) | | Operating margin | % | [(114.4%)](/filings/0000950170-24-029473.md) | [(133.1%)](/filings/0000950170-24-029473.md) | [(225.6%)](/filings/0000950170-25-047800.md) | [(147.4%)](/filings/0001193125-26-151455.md) | [(1143.7%)](/filings/0001193125-26-151455.md) | | Net margin | % | [(282.4%)](/filings/0000950170-24-029473.md) | [(61.4%)](/filings/0000950170-24-029473.md) | [(244.6%)](/filings/0000950170-25-047800.md) | [(128.7%)](/filings/0001193125-26-151455.md) | [(1236.4%)](/filings/0001193125-26-151455.md) | | Diluted EPS | $ per share | [(0.67)](/filings/0000950170-24-029473.md) | [(0.17)](/filings/0000950170-24-029473.md) | [(1.28)](/filings/0000950170-25-047800.md) | [(8.05)](/filings/0001193125-26-151455.md) | [(36.48)](/filings/0001193125-26-151455.md) | | Free cash flow | $m | [(28.7)](/filings/0000950170-24-029473.md) | [(21.3)](/filings/0000950170-24-029473.md) | [(20.7)](/filings/0000950170-25-047800.md) | [19.3](/filings/0001193125-26-151455.md) | [3.7](/filings/0001193125-26-151455.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Gross profit: us-gaap:GrossProfit. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sclx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.4m | 301,292 | | Added +37,242 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $853.5k | 109,417 | | Added +6,621 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $357.4k | 45,822 | | Added +6,164 | | [JACOBS LEVY EQUITY MANAGEMENT, INC](/funds/884414.md) | 2026-06-30 | $321.1k | 41,163 | | New +41,163 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $275.9k | 35,376 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $260.3k | 33,376 | | Added +26,908 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $257.9k | 33,064 | | Reduced −3,800 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $214.5k | 27,497 | | New +27,497 | | [Ashton Thomas Private Wealth, LLC](/funds/2019663.md) | 2026-06-30 | $144.2k | 18,482 | | Added +493 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $117.4k | 15,047 | | Added +14 | ## Recent filings [All 725 filings](/companies/sclx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-29 | 16:07 ET | [8-K](/filings/0001193125-26-407333.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-407333 | | 2026-08-14 | 16:41 ET | [10-Q](/filings/0001193125-26-352464.md) | Quarterly report, period 2026-06-30 | 0001193125-26-352464 | | 2026-08-12 | 17:18 ET | [8-K](/filings/0001193125-26-347186.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-347186 | | 2026-07-22 | 17:30 ET | [8-K](/filings/0001193125-26-312591.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0001193125-26-312591 | | 2026-07-07 | 21:26 ET | [SCHEDULE 13D/A](/filings/0001193125-26-297859.md) | Ownership report, active investor, amended | 0001193125-26-297859 | | 2026-07-06 | 06:15 ET | [8-K](/filings/0001193125-26-295493.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-295493 | | 2026-06-29 | 17:01 ET | [8-K](/filings/0001193125-26-288677.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity | 0001193125-26-288677 | | 2026-06-26 | 16:24 ET | [SCHEDULE 13D/A](/filings/0001193125-26-285542.md) | Ownership report, active investor, amended | 0001193125-26-285542 | | 2026-06-24 | 16:52 ET | [8-K](/filings/0001193125-26-281213.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-281213 | | 2026-05-20 | 17:22 ET | [10-Q](/filings/0001193125-26-232857.md) | Quarterly report, period 2026-03-31 | 0001193125-26-232857 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-151455.md), filed Apr 10, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/1449def0-255e-47f3-83a2-0c83a394d71d) ## About the filer - CIK: 1820190 - Tickers: SCLX, SCLXW - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.